Context: Cushing's syndrome (CS) is a disorder associated with significant morbidity and mortality due to prolonged exposure to high cortisol concentrations.
C
ushing's syndrome (CS), is a serious endocrine disorder that may be caused by a pituitary [Cushing's disease (CD)] or nonpituitary (ectopic) ACTH-secreting tumor or by an adrenal neoplasm. If inadequately treated, CS is associated with a 3.8-to 5.0-fold higher mortality than the general population (1) (2) (3) . Regardless of cause, surgery is usually the treatment of choice; however, complete removal of the neoplasm may not be possible (4, 5) . Adjunctive radiotherapy for CD may take years to control excess cortisol (6) . Laparoscopic bilateral adrenalectomy represents another treatment option. No medical treatments were approved by the U.S. Food and Drug Administration for CS when the study was conducted, but off-label use of several medications is common, including dopamine agonists, somatostatin analogs, and the adrenal steroidogenesis inhibitors (ketoconazole, metyrapone, mitotane, and etomidate) (4, 7) . Ketoconazole and mitotane are effective in many patients, but in CD, doses may need progressive increases due to escape from cortisol blockade. The tolerability of these drugs, especially at higher doses, limits their use in some patients (8, 9) .
Mifepristone (11␤-[P-(dimethylamino)phenyl]-17␤-hydroxy-17-(1-propynyl)estra-4,9-dien-3-one) is a progesterone receptor antagonist that has glucocorticoid receptor antagonist activity at higher concentrations, with more than three times the binding affinity for the glucocorticoid receptor than dexamethasone (10, 11) . It does not bind to the mineralocorticoid receptor (9) . Case reports and small retrospective studies of mifepristone treatment in CS document improvements in abnormal glucose metabolism, psychiatric symptoms, and the somatic changes associated with CS; hypokalemia was the most commonly reported side effect (9, (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . Based on these preliminary findings, an open-label, prospective, multicenter, 6-month study of the safety and efficacy of mifepristone was conducted in patients with endogenous CS refractory to other therapies.
Patients and Methods

Patients
Adults with confirmed endogenous CS who had associated type 2 diabetes mellitus (T2DM), impaired glucose tolerance (IGT), or a diagnosis of hypertension (HTN) were enrolled ( Fig.  1) . Endogenous hypercortisolism was defined as elevated urinary free cortisol on at least two 24-h collections and elevated latenight salivary cortisol and/or lack of suppression with dexamethasone. T2DM was defined as a fasting plasma glucose (FPG) of at least 126 mg/dl (Ն7.0 mmol/liter) on two measurements or a 2-h plasma glucose of at least 200 mg/dl (Ն11.1 mmol/liter) after a 75-g oral glucose tolerance test (oGTT), and IGT was defined as 2-h oGTT glucose value of 140 -199 mg/dl (7.8 -11 .0 mmol/ liter). HTN was defined as systolic blood pressure over 140 mm Hg and/or diastolic blood pressure (DBP) over 90 mm Hg or pharmacologically treated HTN.
At least two of the following signs or symptoms of Cushing's were also necessary for inclusion: Cushingoid appearance (moon facies, dorsocervical fat pad, and plethora), increased body weight or central obesity, proximal muscle weakness, low bone mineral density (T score Ͻ Ϫ1.0), psychiatric symptoms, and skin changes (hirsutism, violaceous striae, or acne).
Patients were excluded for poorly controlled diabetes mellitus [glycated hemoglobin (HbA1c) Ն 11%], poorly controlled HTN (Ͼ170/110 mm Hg), use of drugs to treat hypercortisolism within 1 month of baseline (mitotane for adrenal carcinoma was allowed if on stable dose Ն1 month before entry), uncorrected hypokalemia, or uncontrolled hypothyroidism or hyperthyroidism; also excluded were women with a uterus who required anticoagulants or had hemorrhagic disorders, endometrial hyperplasia, carcinoma, or polyps. Increases or additions of antihyperglycemic medications during the study were not permitted for patients with T2DM/IGT. For patients with HTN, increases or additions of antihypertensive medications were not permitted with the exception of mineralocorticoid receptor antagonists, which were allowed for treating hypokalemia, a known side effect of mifepristone (9) . Changes in or initiation of antidepressant or lipid-lowering medications were not allowed.
The study was approved by the institutional review board at each center and was registered with www.clinicaltrials. gov (NCT00569582). All patients provided written informed consent.
Design
This was a 24-wk, open-label, multicenter study of mifepristone administered as a single daily oral dose. Treatment began at 300 mg/d; if no significant clinical improvement was noted by the investigator, doses could be increased to 600 mg/d on d 14, 900 mg/d at wk 6, and 1200 mg/d at wk 10. Dose interruption and reduction were specified in the protocol for the following adverse events (AEs): adrenal insufficiency (AI), severe hypokalemia, and vaginal bleeding. Temporary glucocorticoid rescue for suspected AI was also allowed.
Assessments
The primary endpoint for patients with CS and T2DM/IGT (C-DM cohort) was the change in area under the curve for glucose (AUC glucose ) on oGTT from baseline to wk 24. Response was defined as at least a 25% decrease in AUC glucose , an amount considered clinically meaningful improvement in glucose control (26). AUC glucose was used because both patients with T2DM and patients with IGT were enrolled, and HbA1c and FPG would not be uniformly applicable. In patients receiving medications for diabetes, administration occurred before the oGTT (other than short-acting insulin and glucagon-like peptide-1 analogs). The primary endpoint for patients with CS and a diagnosis of HTN (C-HT cohort) was the change in DBP from baseline to wk 24; response was defined as DBP decrease of at least 5 mm Hg (mean of two sequential readings). Patients with both T2DM/IGT and HTN were included only in the C-DM cohort.
Key secondary endpoints included clinical response graded by an independent data review board (DRB) at wk 6, 10, 16, and 24 compared with baseline. The DRB consisted of three CS experts who evaluated the following assessments: glucose homeostasis, blood pressure, lipids, weight and body composition change, clinical appearance (acne, hirsutism, striae, and Cushingoid appearance) (27, 28) as rated by the investigators, strength, and neuropsychological [Beck Depression Inventory (BDI)-II and Trail Making Test] (29 -31) and quality of life [Short-Form 36 Health Survey version 2 (SF-36)] (32) parameters. The DRB also reviewed standardized photographs of 34 consenting patients. Visit number after baseline and mifepristone dose were blinded. Each DRB member categorized patient overall status at follow-up visits as worse (Ϫ1), unchanged (0), or having clinically significant improvement (ϩ1) from baseline. If the reviewers' median score was ϩ1, the patient was considered to have clinical improvement.
Blood, urine, and saliva samples were analyzed by a central laboratory (Quest Diagnostics, Collegeville, PA). AUC glucose and AUC insulin were determined using the linear trapezoidal rule; homeostatic model assessment of insulin resistance (HOMA-IR) was calculated (33). Urinary and salivary cortisol levels were assayed with liquid chromatography tandem mass spectrometry [normal ranges, respectively, are 2-42.4 g/24 h (5.5-117 nmol/24 h) and Յ0.09 g/dl (2.5 nmol/liter)]; serum cortisol [normal range is 4 -22 g/dl (110 -607 nmol/24 h)], and ACTH (normal range is 5-27 pg/ml (1.1-5.9 pmol/liter) for females and 7-50 pg/ml (1.5-11 pmol/liter) for males] were measured with immunochemiluminometric assay.
AEs were reviewed every visit, and patients were monitored with vital signs, physical exams, and blood tests; transvaginal ultrasounds were conducted at baseline, wk 24 [or early termination (ET)], and 6 wks after last dose. Pituitary magnetic resonance imaging (MRI) was performed at screening and at wk 10 and 24 (or ET) in patients with CD. Body composition was measured using dual-energy x-ray absorptiometry at baseline and wk 24 or ET using Hologic (Bedford, MA) or GE Lunar (Madison, WI) instruments; results were submitted to a central reading site for quality control and analysis.
Statistics
Patients who took at least one dose of study medication comprised the safety population (n ϭ 50). A modified intent-to-treat (mITT) population (patients who received Ն30 d of study medication) was used for analyses of efficacy (n ϭ 46). The completer population included participants who completed through wk 24 and were at least 80% compliant with study medication (n ϭ 33).
Because there was no placebo group in this study, a responder analysis was conducted. Responder rates were tested against an a priori threshold of 20%, which was chosen based on very low spontaneous response rates in this patient population (Ͻ5%) (34). The null hypothesis was to be rejected if the lower bound of the one-sided binomial 95% confidence interval (CI) of responder rates was over 20%. Because mifepristone blocks rather than lowers cortisol, alternative quantitative endpoints (other than cortisol) were assigned at study entry based on inclusion in either C-DM or C-HT cohorts. Two abnormal oGTTs were required for inclusion in the C-DM group; patients with a diagnosis of HTN and without T2DM/IGT were included in the C-HT group. For statistical analysis, response was defined as at least 25% reduction in AUC glucose for C-DM patients or at least 5 mm Hg reduction in DBP in C-HT patients comparing baseline with wk 24/ET. For patients who did not complete the study or have an ET visit, the last available data were used. ANOVA and t tests were used for analyses of other endpoints. Nonparametric statistical testing was employed for nonnormally distributed data. Change in oGTT curves over the course of the study was modeled by a hierarchical linear mixed model that took into consideration the correlation within subjects. SAS statistical software versions 9.1.3 and 9.2 (Cary, NC) were used. Data are shown as mean Ϯ SD unless otherwise stated.
Results
Patients
From January 2008 to January 2011, 50 patients with CS were enrolled at 17 U.S. centers; 34 completed the study. Forty-three patients had a pituitary source of CS (42 with unsuccessful pituitary surgery, 18 with pituitary radiation, and one without previous surgery), four had ectopic ACTH secretion, and three had adrenal cortical carcinoma. Baseline characteristics are detailed in Tables 1 and 2 . The mean dose Ϯ SD at the final study visit was 732 Ϯ 366 mg/d. Twenty-two subjects received the maximum dose of 1200 mg/d. Dose interruptions occurred in 42% of patients with median duration of 2 d (range 1-39 d). There were 18 dose reductions in 12 patients; reductions occurred most commonly in 300-mg decrements (317 Ϯ 114 mg).
Primary efficacy analyses
Patients with T2DM/IGT
In the C-DM mITT population, AUC glucose decreased by at least 25% on oGTT in 15 of 25 (60%) patients from baseline to wk 24/ET (95% CI lower bound 42%, P Ͻ 0.0001) with a median decrease of 36% [30330.0 mg/ dl⅐120 min (1683.3 mmol/liter⅐120 min) to 20655.0 mg/ dl⅐120 min (1146.4 mmol/liter⅐120 min)] as well as comparable reductions in plasma glucose levels ( Fig. 2 and Table 3 ). Similar reductions in AUC glucose were observed in the C-DM ITT and completer populations. The most common doses among responders at wk 24/ET were 600 mg (40%) and 1200 mg (40%), followed by 300 mg (13.3%) and 900 mg (6.7%). In exploratory analyses we found no relationship between the incremental change in dose from baseline and AUC glucose (see Supplemental Fig.  1 , published on The Endocrine Society's Journals Online web site at http://jcem.endojournals.org).
Patients with HTN
In the C-HT mITT cohort, eight of 21) patients (38.1% achieved the primary endpoint of at least 5 mm Hg decline in DBP (95% CI lower bound 21%, P Ͻ 0.05; Table 3 ). Four patients (two responders) received spironolactone during the study; one nonresponder was on spironolactone at entry and remained on a stable dose throughout the study.
Secondary endpoints
Clinical improvement
The overall clinical improvement response rate as assessed by the DRB in the mITT population was 87% (95% CI lower bound 76%, P Ͻ 0.0001); response rates were similar in the C-DM and C-HT cohorts (Table 3) . Thirty-three patients b For overall clinical improvement (median DRB score ϩ1) at any reviewed visit, the null hypothesis was to be rejected in favor of the alternative if the lower limit of the 95% exact one-sided binomial CI for the responder rate was at least 30%. 87.9%). The mean baseline HbA1c of 7.43 Ϯ 1.52% in the C-DM group decreased to 6.29 Ϯ 0.99% at wk 24/ET (P Ͻ 0.001) (Fig. 3A) . Twelve C-DM patients had an HbA1c over 7% at baseline (mean 8.53 Ϯ 1.11%); of these, nine achieved an HbA1c below 7%, including six reaching an HbA1c of 6% or below. C-DM and C-HT patients were insulin resistant and demonstrated rapid and significant improvements in AUC insulin , which continued throughout the study (Fig. 3B) ; HOMA-IR demonstrated improvements in insulin sensitivity (Fig. 3C ).
Weight and body composition
In the mITT population (n ϭ 46), mean Ϯ SD body weight change from baseline (99.5 kg) to wk 24/ET was Ϫ5.7 Ϯ 7.4% (P Ͻ 0.001) (Fig. 4A) . Twenty-four patients lost at least 5% of their baseline weight, 12 of whom lost at least 10%; 10 patients gained an average of 3.6 Ϯ 3.9%. Waist circumference decreased by Ϫ6.8 Ϯ 5.8 cm (P Ͻ 0.001) in women and Ϫ8.4 Ϯ 5.9 cm in men (P Ͻ 0.001) (Fig. 4B) . Mean percent total body fat declined by 3.6% by wk 24 (P Ͻ 0.001). Absolute fat mass declined by 13.9% (P Ͻ 0.001) for the total body, 15.6% (P Ͻ 0.001) for the trunk, and 17.1% (P Ͻ 0.001) for the abdominal region (Fig. 4C ).
DBP and antihypertensive medications (C-HT and C-DM with HTN)
In addition to the 21 C-HT patients, 19 C-DM patients had a diagnosis of HTN at study entry; 42.5% (17 of 40) of these had a reduction in DBP of at least 5 mm Hg at wk 24/ET compared with baseline, and 27.5% had reductions in antihypertensive medications (50% of patients with a diagnosis of HTN were taking at least two antihyperten- 45.4 Ϯ 12.5, P ϭ 0.01) and physical composite scores (mean 34.9 Ϯ 11.0 vs. 39.1 Ϯ 10.8, P ϭ 0.02).
Hormone and pituitary MRI scan changes
During mifepristone treatment, 72% of the 43 patients with CD had at least a 2-fold increase in ACTH, cortisol, or both; 28% had smaller increases. These changes were observed early (by d 14), plateaued from wk 10 -24, and declined to baseline levels at the follow-up visit 6 wk after discontinuation of mifepristone. Increases in ACTH of at least 2-fold were observed in 62.8% of patients; 33.6% had lesser increases, and 4.7% had no change. Late-night salivary cortisol increased 7.92-fold (1.43) at wk 16, and urinary free cortisol increased 7.70-fold (15.29) at wk 24/ ET. At the 6-wk follow-up visit, ACTH and cortisol (serum and urine) declined to near baseline levels. Patients with ectopic ACTH secretion did not demonstrate increases in ACTH and cortisol in response to mifepristone.
Pituitary MRIs were obtained in 41 CD patients; 17 had visible tumors, 10 of which were macroadenomas, and the remaining 24 did not have demonstrable tumors after surgery. MRIs were stable at wk 10 and 24 in all cases except one. This patient had an aggressive pituitary tumor at baseline that was increased in size at wk 10, leading to treatment discontinuation.
Safety
Overall, AEs were reported in 88% of patients during mifepristone treatment, most commonly nausea (48%), fatigue (48%), headache (44%), decreased blood potassium (34%), arthralgia (30%), vomiting (26%), peripheral edema (26%), HTN (24%), dizziness (22%), decreased appetite (20%), and endometrial thickening (20%). The majority of AEs were considered mild or moderate. Seven patients discontinued mifepristone because of an AE; fatigue was the only cause of discontinuation for more than one patient (n ϭ 2). Interruptions or reductions in mifepristone due to AEs, most commonly nausea (n ϭ 6), occurred in 40% of patients; there were interruptions or reductions for protocol-specified events in four subjects (two for AI, one for severe hypokalemia, and one for vaginal bleeding). After dose interruption or reduction before wk 10, there were increases in dose in one of four and two of five patients, respectively; after wk 10, dose escalation did not occur after an interruption for an AE except in a single patient. Four patients experienced progression of preexisting metastatic malignancy that resulted in death.
AI was reported in two patients. One occurred during an infection and responded to withdrawal of mifepristone; the other resolved with mifepristone withdrawal and dexamethasone administration (6 -9 mg by mouth daily for 6 d). Neither episode was associated with hypoglycemia or hypotension, and mifepristone was restarted at a lower dose. Analysis of AEs and concomitant medications identified five other instances of two or more symptoms possibly consistent with AI during which glucocorticoids were administered. Dexamethasone doses for these episodes ranged from 2-8 mg daily in tapering amounts for 1-12 d. Vaginal bleeding was observed during the study in five premenopausal women. Prolonged metrorrhagia was observed in two of them after discontinuing mifepristone. Endometrial thickening was reported as an AE in 10 women. Three women underwent dilatation and curettage for unresolved endometrial thickening.
Twenty-two patients had a serum potassium level less than 3.5 mEq/liter (Ͻ3.5 mmol/liter), but only three experienced severe hypokalemia [Յ2.5 mEq/liter (Յ2.5 mmol/liter)] during mifepristone treatment, including one serious AE [potassium 2.1 mEq/liter (2.1 mmol/liter)]. Hypokalemia occurred in patients with both ACTH-dependent and independent CS. Four (one adrenal cancer and three ectopic ACTH) of seven patients with nonpituitary CS experienced hypokalemia during treatment. Hypokalemia was often associated with alkalosis and edema and generally responded to potassium replacement (10 -420 mEq daily); all nonpituitary CS patients received potassium supplementation. Overall, spironolactone (50 -400 mg daily) was used by 14 patients; it was started or increased in 11 patients for hypokalemia while taking mifepristone, including one patient with adrenal cancer and two patients with ectopic ACTH secretion. Reversible decreases in high-density lipoprotein cholesterol (HDL-C) and increases in TSH were observed. The mean change in HDL-C from baseline [62.3 Ϯ 27.8 mg/dl (1.61 Ϯ 0.72 mmol/liter)] to wk 24/ET was Ϫ14.2 Ϯ 11.9 mg/dl (0.37 Ϯ 0.31 mmol/liter) (P Ͻ 0.001); there were small declines in low-density lipoprotein cholesterol and triglycerides that were not statistically significant. Eight patients had undetectable TSH at baseline; of the remaining 42 patients, eight had increases in TSH above normal (three with TSH Ͼ 10 U/liter, one with TSH of 32 U/liter). Six weeks after mifepristone discontinuation, both HDL-C and thyroid function tests reverted to baseline levels.
Discussion
Cushing's syndrome is a complex endocrine condition with serious sequelae, including cardiovascular mortality, fractures, proximal myopathy, insulin-resistant hyperglycemia, and neuropsychiatric and neurocognitive disorders (35, 36). Transsphenoidal pituitary surgery with adenoma resection is initially successful in 65-90% of patients with ACTH-secreting microadenomas when performed by ex-pert surgeons, but approximately 20 -25% have persistent hypercortisolism or recurrence postoperatively; cure rates are lower and recurrence rates are higher for macroadenomas (4). Morbidity and mortality in patients with CD are related to cortisol excess and rarely to the ACTHsecreting pituitary tumor mass. When surgery fails to reverse hypercortisolemia, medical treatment can suppress cortisol overproduction and improve clinical manifestations. Bilateral adrenalectomy promptly resolves hypercortisolism but causes permanent adrenal cortical insufficiency mandating lifelong corticosteroid and mineralocorticoid replacement therapy. It may also decrease quality of life (5, 37) and can result in an enlargement of an ACTH-secreting pituitary tumor in 15-20% of cases (38). Patients with ectopic ACTH-secreting neoplasms or adrenocortical carcinoma often require control of hypercortisolism while waiting for definitive therapy or if definitive therapy is not feasible (39).
Mifepristone, a glucocorticoid receptor antagonist with binding affinity greater than dexamethasone and cortisol (10, 11) , is rapidly absorbed orally, highly protein bound, and has a long half-life (40). The use of mifepristone in CS has been explored in case reports and/or small retrospective studies (9, (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) . This is the largest prospective multicenter trial of mifepristone and demonstrates effectiveness in treating the clinical and metabolic derangements associated with hypercortisolism.
The two primary study endpoints were met: mifepristone significantly decreased AUC glucose during oGTT in patients with CS and T2DM or IGT and decreased DBP in a significant number of patients with CS and HTN. Significant decreases in FPG and HbA1c occurred in the C-DM cohort, and more than half the hypertensive patients in both groups had either an improvement in DBP or a reduction in antihypertensive medication. However, overall, there was no change in mean blood pressure from baseline to end of study.
As expected with a receptor-blocking strategy, ACTH and cortisol levels increased in patients with CD. Because high cortisol may not be completely inactivated by 11␤-hydroxysteroid dehydrogenase type 2 in the kidney, excess cortisol may activate the mineralocorticoid receptor (41). This likely explains the increased blood pressure, hypokalemia, edema, and alkalosis seen in some patients; nine of the 12 patients with increased blood pressure were prescribed spironolactone.
Secondary endpoint results were noteworthy: mifepristone significantly decreased body weight, waist circumference, and body fat and increased insulin sensitivity. Clinically significant improvement was seen in 87% of patients, according to well-defined criteria used by the DRB. Moreover, 30 of the 34 patients who completed the 24-wk study elected to continue treatment with mifepristone.
Weight loss observed in the study may have been partially due to commonly experienced nausea and decreased appetite (see Supplemental Fig. 3 ) as well as to a direct result of glucocorticoid blockade. Moreover, it is not possible to discern whether these AEs result from medication or secondarily through a therapeutic effect of glucocorticoid withdrawal. Although clinically significant AI is a potential side effect of glucocorticoid receptor antagonism (9) , it was uncommon during this study. Only two patients were reported to have AI; possible symptoms of AI including anorexia, nausea, lethargy, and dizziness occurred in five additional patients who also received glucocorticoids. It is important to note that cortisol elevations that occur in CD could be misleading and render the diagnosis of AI difficult. Without any available biochemical marker, these patients require close monitoring during treatment.
Decreased HDL-C and increased TSH were observed in some patients; these abnormalities resolved upon discontinuation of mifepristone. Because of its antiprogesterone effects, mifepristone has an impact on the endometrium characterized by thickening, with cystically dilated endometrial glands and features usually seen separately in normal proliferative and secretory endometrium (42). Ten women had AE of endometrial thickening, and abnormal vaginal bleeding occurred in five patients. An ongoing, long-term extension study will further characterize the safety profile of mifepristone in CS.
With the exception of a very aggressive tumor in one patient, there were no increases in tumor size, but it is important to note that the study duration was only 6 months. Data from longer-term use of mifepristone will be required to determine whether this risk is similar to that after bilateral adrenalectomy (38).
Limitations of the study include the lack of a placebo comparator group, the open-label design, exclusion of patients with de novo Cushing's who were candidates for surgery, and the small number of adrenal cancer and ectopic ACTH cases. The dosing scheme allowing investigators to use their clinical judgment regarding increasing mifepristone based on benefit vs. tolerance produced heterogeneity in management, which is a limitation of the study. Similarly, interruptions or reduction in the dose of mifepristone to manage AE produced additional dosing pattern heterogeneity. An assessment of dose response overall was therefore not possible.
Glucocorticoid receptor antagonism with mifepristone may offer a new approach to control the clinical manifestations of endogenous hypercortisolism in patients who have not responded to multimodal therapies. Although the side effect profile over 6 months is well characterized and manageable with additional medications, the long-term efficacy and safety remain to be determined, particularly with regard to the need for potassium supplementation and/or mineralocorticoid receptor blockade and endometrial monitoring. Because mifepristone does not decrease cortisol production, measurement of this hormone should not be performed during treatment; careful monitoring by clinicians familiar with the mechanism of action of this unique agent is essential. Long-term data are needed to further define the role of mifepristone in the medical treatment of CS. 
HIGHLIGHTS OF PRESCRIBING INFORMATION
These highlights do not include all the information needed to use Korlym ® safely and effectively. See full prescribing information for Korlym. Korlym ® (mifepristone) 300 mg Tablets Initial U.S Approval 2000
WARNING: TERMINATION OF PREGNANCY
See full prescribing information for complete boxed warning.
Mifepristone has potent antiprogestational effects and will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with Korlym, or if treatment is interrupted for more than 14 days in females of reproductive potential.
INDICATIONS AND USAGE
Korlym (mifepristone) is a cortisol receptor blocker indicated to control hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Important Limitations of Use
• Do not use for the treatment of type 2 diabetes mellitus unrelated to endogenous Cushing's syndrome.
DOSAGE AND ADMINISTRATION • Administer once daily orally with a meal (2).
• The recommended starting dose is 300 mg once daily (2).
• Renal impairment: do not exceed 600 mg once daily.
• Mild-to-moderate hepatic impairment: do not exceed 600 mg once daily. Do not use in severe hepatic impairment.
Based on clinical response and tolerability, the dose may be increased in 300 mg increments to a maximum of 1200 mg once daily. Do not exceed 20 mg/kg per day (2).
DOSAGE FORMS AND STRENGTHS
• 300 mg tablet 
WARNINGS AND PRECAUTIONS
• Adrenal insufficiency : Patients should be closely monitored for signs and symptoms of adrenal insufficiency (5.1). • Hypokalemia: Hypokalemia should be corrected prior to treatment and monitored for during treatment (5.2
DRUG INTERACTIONS
• Drugs metabolized by CYP3A: Administer drugs that are metabolized by CYP3A at the lowest dose when used with Korlym (7.1).
• CYP3A inhibitors: Caution should be used when Korlym is used with strong CYP3A
inhibitors. Limit mifepristone dose to 300 mg per day when used with strong CYP3A inhibitors (5.6, 7.2). • CYP3A inducers: Do not use Korlym with CYP3A inducers (7.3).
• Drugs metabolized by CYP2C8/2C9: Use the lowest dose of CYP2C8/2C9 substrates when used with Korlym (7.4).
• Drugs metabolized by CYP2B6: Use of Korlym should be done with caution with bupropion and efavirenz (7.5).
• Hormonal contraceptives: Do not use with Korlym (7.6). Mifepristone is a potent antagonist of progesterone and cortisol via the progesterone and glucocorticoid (GR-II) receptors, respectively. The antiprogestational effects will result in the termination of pregnancy. Pregnancy must therefore be excluded before the initiation of treatment with Korlym and prevented during treatment and for one month after stopping treatment by the use of a non-hormonal medically acceptable method of contraception unless the patient has had a surgical sterilization, in which case no additional contraception is needed. Pregnancy must also be excluded if treatment is interrupted for more than 14 days in females of reproductive potential.
USE IN SPECIFIC POPULATIONS
INDICATIONS AND USAGE
LIMITATIONS OF USE:
• Korlym should not be used in the treatment of patients with type 2 diabetes unless it is secondary to Cushing's syndrome.
DOSAGE AND ADMINISTRATION 2.1 Adult Dosage
The recommended starting dose is 300 mg orally once daily. Korlym must be given as a single daily dose. Korlym should always be taken with a meal. Patients should swallow the tablet whole. Do not split, crush, or chew tablets.
Dosing and titration
The daily dose of Korlym may be increased in 300 mg increments. The dose of Korlym may be increased to a maximum of 1200 mg once daily but should not exceed 20 mg/kg per day. Increases in dose should not occur more frequently than once every 2-4 weeks. Decisions about dose increases should be based on a clinical assessment of tolerability and degree of improvement in Cushing's syndrome manifestations. Changes in glucose control, antidiabetic medication requirements, insulin levels, and psychiatric symptoms may provide an early assessment of response (within 6 weeks) and may help guide early dose titration. Improvements in cushingoid appearance, acne, hirsutism, striae, and body weight occur over a longer period of time and, along with measures of glucose control, may be used to determine dose changes beyond the first 2 months of therapy. 
DOSAGE FORMS AND STRENGTHS
Korlym is supplied as a light yellow to yellow oval-shaped tablet debossed with "Corcept" on one side and "300" on the other. Each tablet contains 300 mg of mifepristone. The tablets are not scored. 
CONTRAINDICATIONS 4.1 Pregnancy
.3 Corticosteroid Therapy Required for Lifesaving Purposes
Korlym is contraindicated in patients who require concomitant treatment with systemic corticosteroids for serious medical conditions or illnesses (e.g., immunosuppression after organ transplantation) because Korlym antagonizes the effect of glucocorticoids.
Women with Risk of Vaginal Bleeding or Endometrial Changes
Korlym is contraindicated in the following:
• Women with a history of unexplained vaginal bleeding • Women with endometrial hyperplasia with atypia or endometrial carcinoma 4.5 Known Hypersensitivity to Mifepristone Korlym is contraindicated in patients with prior hypersensitivity reactions to mifepristone or to any of the product components.
WARNINGS AND PRECAUTIONS 5.1 Adrenal Insufficiency
Patients receiving mifepristone may experience adrenal insufficiency. Because serum cortisol levels remain elevated and may even increase during treatment with Korlym, serum cortisol levels do not provide an accurate assessment of hypoadrenalism in patients receiving Korlym. 
Potential Effects of Hypercortisolemia
Korlym does not reduce serum cortisol levels. Elevated cortisol levels may activate mineralocorticoid receptors which are also expressed in cardiac tissues. Caution should be used in patients with underlying heart conditions including heart failure and coronary vascular disease.
ADVERSE REACTIONS 6.1 Clinical Trials Experience
Because clinical trials are conducted under widely varying conditions, the adverse reaction rates observed cannot be directly compared to rates in other clinical trials and may not reflect the rates observed in clinical practice. Safety data on the use of Korlym are available from 50 patients with Cushing's syndrome enrolled in an uncontrolled, open-label, multi-center trial (Study 400). Forty-three patients had Cushing's disease and all except one had previously undergone pituitary surgery. Four patients had ectopic ACTH secretion, and three had adrenal carcinoma. Patients were treated for up to 24 weeks. A dose of 300 mg per day was administered for the initial 14 days; thereafter, the dose could be escalated in increments of 300 mg per day based on assessments of tolerability and clinical response. Doses were escalated up to 900 mg per day for patients <60 kg, or 1200 mg per day for patients >60 kg. The most frequently reported adverse reactions (reported in ≥20% of patients, regardless of relationship to Korlym) were nausea, fatigue, headache, decreased blood potassium, arthralgia, vomiting, peripheral edema, hypertension, dizziness, decreased appetite, and endometrial hypertrophy. Drug-related adverse events resulted in dose interruption or reduction in study drug in 40% of patients.
The adverse reactions that occurred in ≥10% of the Cushing's syndrome patients receiving Korlym, regardless of relationship to Korlym, are shown in Table 1 . 
Laboratory Tests
Reductions in high density lipoprotein-cholesterol (HDL-C) levels have been observed following treatment with Korlym. In study subjects that experienced declines in HDL-C, levels returned to baseline following discontinuation of drug. The clinical significance of the treatment-related reduction in HDL-C levels in patients with Cushing's syndrome is not known. In a study of patients with Cushing's syndrome, hypokalemia was observed in 44% of subjects during treatment with Korlym. In these cases, hypokalemia responded to treatment with potassium supplementation and/or mineralocorticoid antagonist therapy (e.g., spironolactone or eplerenone). Hypokalemia should be corrected prior to initiating Korlym.
[See Warnings and Precautions (5.2)]
Elevations of thyroid-stimulating hormone (TSH) were seen in subjects treated with Korlym.
Of the 42 subjects with detectable TSH at baseline, eight (19%) had increases in TSH above the normal range, while remaining asymptomatic. The TSH levels returned to normal in most patients without intervention when Korlym was discontinued at the end of the study.
Vaginal Bleeding and Endometrial Changes
In Study 400, the thickness of the endometrium increased from a mean of 6.14 mm at baseline (n=23) to 15.7 mm at end-of-trial (n=18) in premenopausal women; in postmenopausal women the increase was from 2.75 mm (n=6) to 7.35 mm (n=8). Endometrial thickness above the upper limit of normal was reported in 10/26 females who had baseline and end-of-trial transvaginal ultrasound (38%). The endometrial thickness returned to the normal range in 3 out of 10 patients 6 weeks after treatment cessation at the end of the study. Vaginal bleeding occurred in 5 out of 35 females (14%). Two of five subjects with vaginal bleeding had normal endometrial thickness. Endometrial biopsies were performed in six patients; five of these patients had endometrial thickening. No endometrial carcinoma was detected in the sampled cases.
Additional Data from Clinical Trials
The following are adverse events that were reported in Study 400 at frequencies of ≥ 5% to 10%, and may be related to Korlym's mechanism of action: 
.1 Adrenal Insufficiency
Adrenal insufficiency was reported in two subjects (4%) in Study 400. The most typical symptoms of adrenal insufficiency were nausea and decreased appetite. No hypotension or hypoglycemia was reported during the events. Adrenal insufficiency resolved in both cases with Korlym interruption and/or dexamethasone administration.
Rash
Generalized, maculo-papular rash was reported in 2 subjects (4%) in Study 400. Two additional subjects developed pruritus (4%). None resulted in discontinuation of Korlym, and all the events resolved by the end of the study. Ketoconazole and other strong inhibitors of CYP3A, such as itraconazole, nefazodone, ritonavir, nelfinavir, indinavir, atazanavir, amprenavir and fosamprenavir, boceprevir, clarithromycin, conivaptan, lopinavir, mibefradil, posaconazole, saquinavir, telaprevir, telithromycin, or voriconazole may increase exposure to mifepristone significantly. The clinical impact of this interaction has not been studied. Therefore, extreme caution should be used when these drugs are prescribed in combination with Korlym. The benefit of concomitant use of these agents should be carefully weighed against the potential risks. The dose of Korlym should be limited to 300 mg and used only when necessary.
DRUG INTERACTIONS
Based on the long terminal half-life of mifepristone after reaching steady state, at least 2 weeks should elapse after cessation of Korlym before initiating or increasing the dose of any interacting concomitant medication. 7.1 Drugs Metabolized by CYP3A Because Korlym is an inhibitor of CYP3A, concurrent use of Korlym with a drug whose metabolism is
[See Warnings & Precautions (5.6)]
Moderate inhibitors of CYP3A, such as amprenavir, aprepitant, atazanavir, ciprofloxacin, darunavir/ritonavir, diltiazem, erythromycin, fluconazole, fosamprenavir, grapefruit juice, imatinib, or verapamil, should be used with caution when administered in combination with Korlym.
CYP3A Inducers
No medications that induce CYP3A have been studied when co-administered with Korlym. Avoid co-administration of Korlym and CYP3A inducers such as rifampin, rifabutin, rifapentin, phenobarbital, phenytoin, carbamazepine, and St. John's wort.
Drugs Metabolized by CYP2C8/2C9
Because Korlym is an inhibitor of CYP2C8/2C9, concurrent use of Korlym with a drug whose metabolism is largely or solely mediated by CYP2C8/2C9 is likely to result in increased plasma concentrations of the drug. Korlym significantly increased exposure of fluvastatin, a typical CYP2C8/2C9 substrate, in healthy subjects. When given concomitantly with Korlym, drugs that are substrates of CYP2C8/2C9 (including non-steroidal anti-inflammatory drugs, warfarin, and repaglinide) should be used at the smallest recommended doses, and patients should be closely monitored for adverse effects.
[See Clinical Pharmacology (12. 3)]
Drugs Metabolized by CYP2B6
Mifepristone is an inhibitor of CYP2B6 and may cause significant increases in exposure of drugs that are metabolized by CYP2B6 such as bupropion and efavirenz. Since no study has been conducted to evaluate the effect of mifepristone on substrates of CYP2B6, the concomitant use of bupropion and efavirenz should be undertaken with caution.
Use of Hormonal Contraceptives
Mifepristone is a progesterone-receptor antagonist and will interfere with the effectiveness of hormonal contraceptives. Therefore, non-hormonal contraceptive methods should be used. 
Animal Data
Teratology studies in mice, rats and rabbits at doses of 0.25 to 4.0 mg/kg (less than human exposure at the maximum clinical dose, based on body surface area) were carried out.
Because of the anti-progestational activity of mifepristone, fetal losses were much higher than in control animals. Skull deformities were detected in rabbit studies at less than human exposure, although no teratogenic effects of mifepristone have been observed to date in rats or mice. These deformities were most likely due to the mechanical effects of uterine contractions resulting from antagonism of the progesterone receptor.
Nursing Mothers
Mifepristone is present in human milk of women taking the drug. Because of the potential for serious adverse reactions in nursing infants from Korlym, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.
Pediatric Use
Safety and effectiveness of Korlym in pediatric patients have not been established.
Geriatric Use
Clinical studies with Korlym did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently than younger people.
Renal Impairment
The maximum dose should not exceed 600 mg per day in renally impaired patients.
[See Clinical Pharmacology (12. 3)] 8.7 Hepatic Impairment In patients with mild to moderate hepatic impairment, the maximum dose should not exceed 600 mg per day. The pharmacokinetics of mifepristone in patients with severe hepatic impairment has not been studied, and Korlym should not be used in these patients.
[See Clinical Pharmacology (12. 3)] 8.8 Females of Reproductive Potential Due to its anti-progestational activity, Korlym causes pregnancy loss. Exclude pregnancy before the initiation of treatment with Korlym or if treatment is interrupted for more than 14 days in females of reproductive potential. Recommend contraception for the duration of treatment and for one month after stopping treatment using a non-hormonal medically acceptable method of contraception. If the patient has had surgical sterilization, no additional contraception is needed.
OVERDOSAGE
There is no experience with overdosage of Korlym.
DESCRIPTION
Korlym (mifepristone) is a cortisol receptor blocker for oral administration. The chemical name of mifepristone is 11ß-(4-dimethylaminophenyl)-17ß-hydroxy-17-(1-propynyl)-estra-4,9-dien-3-one. The chemical formula is C 29 H 35 NO 2 ; the molecular weight is 429.60, and the structural formula is:
Mifepristone demonstrates a pH-related solubility profile. The greatest solubility is achieved in acidic media (~ 25 mg/mL at pH 1.5) and solubility declines rapidly as the pH is increased. At pH values above 2.5 the solubility of mifepristone is less than 1 mg/mL. Each Korlym tablet for oral use contains 300 mg of mifepristone. The inactive ingredients of Korlym tablets are silicified microcrystalline cellulose, sodium starch glycolate, hydroxypropylcellulose, sodium lauryl sulfate, magnesium stearate, hypromellose, titanium dioxide, triacetin, D&C yellow 10 aluminum lake, polysorbate 80, and FD&C yellow 6 aluminum lake.
CLINICAL PHARMACOLOGY 12.1 Mechanism of Action
Mifepristone is a selective antagonist of the progesterone receptor at low doses and blocks the glucocorticoid receptor (GR-II) at higher doses. Mifepristone has high affinity for the GR-II receptor but little affinity for the GR-I (MR, mineralocorticoid) receptor. In addition, mifepristone appears to have little or no affinity for estrogen, muscarinic, histaminic, or monoamine receptors.
Pharmacodynamics
Because mifepristone acts at the receptor level to block the effects of cortisol, its antagonistic actions affect the hypothalamic-pituitary-adrenal (HPA) axis in such a way as to further increase circulating cortisol levels while, at the same time, blocking their effects. Mifepristone and the three active metabolites have greater affinity for the glucocorticoid receptor (100%, 61%, 48%, and 45%, respectively) than either dexamethasone (23%) or cortisol (9%).
Pharmacokinetics Absorption
Following oral administration, time to peak plasma concentrations of mifepristone occurred between 1 and 2 hours following single dose, and between 1 and 4 hours following multiple doses of 600 mg of Korlym in healthy volunteers. Mean plasma concentrations of three active metabolites of mifepristone peak between 2 and 8 hours after multiple doses of 600 mg/day, and the combined concentrations of the metabolites exceed that of the parent mifepristone. Exposure to mifepristone is substantially less than dose proportional. Time to steady state is within 2 weeks, and the mean (SD) half-life of the parent mifepristone was 85 (61) hours following multiple doses of 600 mg/day of Korlym. Studies evaluating the effects of food on the pharmacokinetics of Korlym demonstrate a significant increase in plasma levels of mifepristone when dosed with food. To achieve consistent plasma drug concentrations, patients should be instructed to always take their medication with meals.
Distribution
Mifepristone is highly bound to alpha-1-acid glycoprotein (AAG) and approaches saturation at doses of 100 mg (2.5 µM) or more. Mifepristone and its metabolites also bind to albumin and are distributed to other tissues, including the central nervous system (CNS). As determined in vitro by equilibrium dialysis, binding of mifepristone and its three active metabolites to human plasma proteins was concentration-dependent. 
Drug-Drug Interactions In Vitro Assessment of Drug Interactions
In vitro studies indicate a potential for CYP-mediated drug interactions by mifepristone and/ or its metabolites with substrates of CYP2A6, CYP2C8/2C9, CYP2C19, CYP3A4, CYP1A2, CYP2B6, CYP2D6, and CYP2E1. In vitro studies also indicated an interaction potential for drug transport mediated by P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP). In vitro studies indicate mifepristone metabolism is mediated by CYP3A, and that mifepristone also inhibits and induces CYP3A.
In Vivo Assessment of Drug Interactions (see Table 2 ) 2 Result could be representative of other oral drugs with CYP3A metabolism and low first pass effect. Clinical significance of any interaction will depend on the therapeutic margin of the drug. 3 Result could be representative of other oral drugs with CYP2C8/C9 metabolism 4 Plasma digoxin concentration should be measured after 1 to 2 weeks of concomitant use and following usual clinical practice at appropriate intervals thereafter. 5 Result could be representative of other mild inhibitors of CYP3A 13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Mifepristone was evaluated for carcinogenicity potential in rats and mice. Rats were dosed for up to two years at doses of 5, 25, and 125 mg/kg of mifepristone. The high dose was the maximum tolerated dose, but exposure at all doses was below exposure at the maximum clinical dose based on AUC comparison. Female rats had a statistically significant increase in follicular cell adenomas/ carcinomas and liver adenomas. It is plausible that these tumors are due to drug-induced enzyme metabolism, a mechanism not considered clinically relevant, but studies confirming this mechanism were not conducted with mifepristone. Mice were also tested for up to 2 years at mifepristone doses up to the maximum tolerated dose of 125 mg/kg, which provided exposure below the maximum clinical dose based on AUC. No drug-related tumors were seen in mice. Mifepristone was not genotoxic in a battery of bacterial, yeast, and mammalian in vitro assays, and an in vivo micronucleus study in mice. The pharmacological activity of mifepristone disrupts the estrus cycle of adult rats at a dose of 0.3 mg/kg (less than human exposure at the maximum clinical dose, based on body surface area). However, following withdrawal of treatment and subsequent resumption of the estrus cycle, there was no effect on reproductive function when mated. A single subcutaneous dose of mifepristone (up to 100 mg/kg) to rats on the first day after birth did not adversely affect future reproductive function in males or females, although the onset of puberty was slightly premature in dosed females. Repeated doses of mifepristone (1 mg every other day) to neonatal rats resulted in potentially adverse fertility effects, including oviduct and ovary malformations in females, delayed male puberty, deficient male sexual behavior, reduced testicular size, and lowered ejaculation frequency.
14 CLINICAL STUDIES 14.1 Cushing's Syndrome
An uncontrolled, open-label, 24-week, multicenter clinical study was conducted to evaluate the safety and efficacy of Korlym in the treatment of endogenous Cushing's syndrome. The study enrolled 50 subjects with clinical and biochemical evidence of hypercortisolemia despite prior surgical treatment and radiotherapy. The reasons for medical treatment were failed surgery, recurrence of disease, and poor medical candidate for surgery. Forty-three patients (86%) had Cushing's disease, four patients (8%) had ectopic ACTH secretion, and three (6%) had adrenal carcinoma. Baseline characteristics included: mean age of 45 years (range 26 to 71), mean BMI of 36 kg/m 2 (range 24 to 66), mean weight 100 kg (range 61 to 199), and mean waist circumference was 119 cm (range 89 to 178); 70% were female; 84% were white and 16% were black or African American. Baseline mean urinary free cortisol level was 365 µg per 24 hr. Patients belonged to one of two cohorts: a "diabetes" cohort (29 patients, 26 with type 2 diabetes and 3 with glucose intolerance), and a "hypertension" cohort (21 patients). Efficacy was evaluated separately in the two cohorts. Korlym treatment was started in all patients at a dose of 300 mg once a day. The study protocol allowed an increase in dose to 600 mg after 2 weeks, and then by additional 300 mg increments every 4 weeks to a maximum of 900 mg per day for patients <60 kg, or 1200 mg per day for patients >60 kg, based on clinical tolerance and clinical response.
Results in the diabetes cohort
Patients in the diabetes cohort underwent standard oral glucose tolerance tests at baseline and periodically during the clinical study. Anti-diabetic medications were allowed but had to be kept stable during the trial and patients had to be on stable anti-diabetic regimens prior to enrollment. The primary efficacy analysis for the diabetes cohort was an analysis of responders. A responder was defined as a patient who had a ≥25% reduction from baseline in glucose AUC. The primary efficacy analysis was conducted in the modified intent-to-treat population (n=25) defined as all patients who received a minimum of 30 days on Korlym. Fifteen of 25 patients (60%) were treatment responders (95% CI: 39%,78%). Mean HbA1c was 7.4% in the 24 patients with HbA1c values at baseline and Week 24. For these 24 patients mean reduction in HbA1c was 1.1% (95% CI -1.6, -0.7) from baseline to the end of the trial. Fourteen of 24 patients had above normal HbA1c levels at baseline, ranging between 6.7% and 10.4%; all of these patients had reductions in HbA1c by the end of the study (range -0.4 to -4.4%) and eight of 14 patients (57%) normalized HbA1c levels at trial end. Antidiabetic medications were reduced in 7 of the 15 DM subjects taking antidiabetic medication and remained constant in the others.
Results in the hypertension cohort
There were no changes in mean systolic and diastolic blood pressures at the end of the trial relative to baseline in the modified intent-to-treat population (n=21).
Signs and symptoms of Cushing's syndrome in both cohorts
Individual patients showed varying degrees of improvement in Cushing's syndrome manifestations such as cushingoid appearance, acne, hirsutism, striae, psychiatric symptoms, and excess total body weight. Because of the variability in clinical presentation and variability of response in this open label trial, it is uncertain whether these changes could be ascribed to the effects of Korlym.
HOW SUPPLIED/STORAGE AND HANDLING
Korlym is supplied as a light yellow to yellow, film-coated, oval-shaped tablet debossed with "Corcept" on one side and "300" on the other. Each tablet contains 300 mg of mifepristone. 
Importance of Preventing Pregnancy
• Advise patients that Korlym will cause termination of pregnancy. Korlym is contraindicated in pregnant patients.
• Counsel females of reproductive potential regarding pregnancy prevention and planning with a non-hormonal contraceptive prior to use of Korlym and up to one month after the end of treatment.
• Instruct patients to contact their physician immediately if they suspect or confirm they are pregnant. Tell your doctor about all of the medicines you take, including prescription and nonprescription medicines, vitamins and herbal supplements. Using Korlym with certain other medicines can affect each other. Using Korlym with other medicines can cause serious side effects.
